3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Extranodal NK-T-Cell
1
Klatskin Tumor
1
Cirrhosis, Familial, with Pulmonary Hypertension
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Interventions
Lenalidomide
5
Rituximab
4
Brentuximab Vedotin
4
Vincristine
3
Etoposide
3
Cyclophosphamide
3
romidepsin
2
Vorinostat
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Doxorubicin
2
Dasatinib
2
tislelizumab
1
selinexor
1
plerixafor
1
pembrolizumab
1
pegfilgrastim
1
parsaclisib
1
obinutuzumab
1
obatoclax
1
monomethyl auristatin E
1
liposomal doxorubicin
1
ixazomib
1
idelalisib
1
ibrutinib
1
gemcitabine-oxaliplatin regimen
1
fludarabine
1
etoposide phosphate
1
denileukin diftitox
1
copanlisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, T-Cell, Peripheral
×
gemcitabine-oxaliplatin regimen
×
Clear all
NCT04425070
2026-01-05
TOUCH
Antengene Corporation
Phase 1/2
Terminated
56 enrolled